Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Assets: 2013-2025

Historic Other Non-Current Assets for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $939,000.

  • Aytu Biopharma's Other Non-Current Assets fell 52.36% to $939,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $939,000, marking a year-over-year decrease of 52.36%. This contributed to the annual value of $1.2 million for FY2025, which is 44.90% down from last year.
  • Latest data reveals that Aytu Biopharma reported Other Non-Current Assets of $939,000 as of Q3 2025, which was down 22.01% from $1.2 million recorded in Q2 2025.
  • Aytu Biopharma's Other Non-Current Assets' 5-year high stood at $2.5 million during Q2 2023, with a 5-year trough of $164,954 in Q1 2021.
  • Over the past 3 years, Aytu Biopharma's median Other Non-Current Assets value was $1.2 million (recorded in 2025), while the average stood at $1.4 million.
  • Data for Aytu Biopharma's Other Non-Current Assets shows a peak YoY increase of 2,752.15% (in 2021) and a maximum YoY decrease of 97.10% (in 2021) over the last 5 years.
  • Over the past 5 years, Aytu Biopharma's Other Non-Current Assets (Quarterly) stood at $457,000 in 2021, then soared by 79.65% to $821,000 in 2022, then grew by 10.48% to $907,000 in 2023, then soared by 67.81% to $1.5 million in 2024, then slumped by 52.36% to $939,000 in 2025.
  • Its Other Non-Current Assets was $939,000 in Q3 2025, compared to $1.2 million in Q2 2025 and $1.3 million in Q1 2025.